[Variation in CEA Values because of Differences in CEA Measurement Methods]

Area of Science:

• Oncology
• Clinical Chemistry
• Biomarker Analysis

Context:

• Carcinoembryonic antigen (CEA) is a vital biomarker in colorectal cancer (CRC) management.
• Assay methods for CEA have evolved, necessitating an evaluation of their impact on reported values.
• Inter-method variability can affect clinical interpretation and patient care.

Purpose:

• To evaluate the changes in carcinoembryonic antigen (CEA) values resulting from a switch in measurement methods.
• To quantify the difference between CEA levels obtained using an old assay method and a new assay method.

Summary:

• A study involving 163 colorectal cancer patients compared old and new CEA assay methods.
• The new assay method (Alinity i system, CEA-Abbott) demonstrated significantly higher CEA values compared to the old method (Centaur XP/XPT, ADVIA Centaur CEA).
• The mean CEA increased from 2.06 ng/mL to 3.14 ng/mL (p<0.0001), with 99.3% of new values exceeding old values.

Impact:

• Findings highlight the critical need to acknowledge assay-specific differences in CEA levels.
• This information is essential for consistent interpretation of CEA trends in colorectal cancer patients.
• Clinicians should be aware of potential shifts in CEA values due to assay method changes to ensure appropriate patient management.